Abivax SA's market cap is currently ―. The company's EPS TTM is €-3.43; its P/E ratio is -4.30; Abivax SA is scheduled to report earnings on September 9, 2024, and the estimated EPS forecast is €-1.55. See an overview of income statement, balance sheet, and cash flow financials.

	Dec 23	Sep 23	Jun 23	Dec 22	Jun 22
Income Statement	-
Total Revenue	-	€ 688.00M	-	-	-
Gross Profit	-	€ 688.00M	-	-	-
EBIT	-	-	-	-	-
EBITDA	-	-	-	-	-
Net Income Common Stockholders	-	€ -77.00M	-	-	-
Balance Sheet	-
Cash, Cash Equivalents and Short-Term Investments	€ 251.94M	€ 244.00M	€ 114.38M	€ 26.95M	€ 26.57M
Total Assets	€ 327.06M	€ 6.89B	€ 171.08M	€ 75.54M	€ 71.64M
Total Debt	€ 55.47M	€ 2.83B	€ 14.72M	€ 19.83M	€ 48.86M
Net Debt	€ -196.48M	€ 2.59B	€ -99.66M	€ -7.12M	€ 22.29M
Total Liabilities	€ 131.05M	€ 4.53B	€ 90.59M	€ 68.36M	€ 65.56M
Stockholders Equity	€ 196.01M	€ 2.28B	€ 80.49M	€ 7.19M	€ 6.08M
Cash Flow	-
Free Cash Flow	-	€ 141.00M	-	-	-
Operating Cash Flow	-	€ 181.00M	-	-	-
Investing Cash Flow	-	€ -70.00M	-	-	-
Financing Cash Flow	-	€ -62.00M	-	-	-

Currency in EUR

Abivax SA Earnings and Revenue History

Income Statement >

Abivax SA Debt to Assets

Balance Sheet >

Abivax SA Cash Flow

Cash Flow >

Abivax SA Forecast EPS vs Actual EPS

Earnings >

Get More with TipRanks Premium

What's Included in PREMIUM?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing